Falsey A R
Department of Medicine, Rochester General Hospital, NY 14621, USA.
Vaccine. 1998 Nov;16(18):1775-8. doi: 10.1016/s0264-410x(98)00142-x.
Respiratory Syncytial Virus (RSV) is an increasingly recognized cause of serious disease in older adults. RSV causes excess morbidity and mortality in older persons residing in nursing homes and in the community. The study of RSV in adults has been hampered by the lack of sensitive methods for the diagnosis of acute infections. Such tools are needed to better understand the epidemiology and immunology of RSV in adults. The immune status of older adults has begun to be explored and preliminary data indicates that low serum neutralizing antibody may predispose to symptomatic RSV infection and that a greater diversity of antibody titres may be seen in the elderly compared to young adults. PFP-2, a candidate RSV subunit vaccine, has been evaluated in healthy and institutionalized elderly and been found to be safe and immunogenic.
呼吸道合胞病毒(RSV)是老年人严重疾病的一个日益被认识到的病因。RSV在居住在养老院和社区的老年人中导致额外的发病率和死亡率。由于缺乏用于诊断急性感染的灵敏方法,对成人RSV的研究受到了阻碍。需要这样的工具来更好地了解成人RSV的流行病学和免疫学。老年人的免疫状态已开始被探索,初步数据表明血清中和抗体水平低可能易患有症状的RSV感染,并且与年轻人相比,老年人的抗体滴度可能具有更大的多样性。候选RSV亚单位疫苗PFP - 2已在健康和机构养老的老年人中进行了评估,结果发现它安全且具有免疫原性。